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Whether this is going astray re-
mains between theoretical pureness and
practical clinical reality, but we felt that
pointing out these reflections to clini-
cians was a useful exercise.
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Bevacizumab
Chemotherapy for
Pulmonary Epithelioid
Hemangioendothelioma
with Severe Dyspnea
To the Editor:
In past issues of the Journal of
Thoracic Oncology,1,2 two case reports
described the controversial efficacy of
combination chemotherapy with carbopla-
tin, paclitaxel, and bevacizumab (BV) for
patients with pulmonary epithelioid he-
mangioendothelioma (PEH). Recently,
we encountered a patient with PEH and
severe dyspnea for which a similar reg-
imen was transiently effective for im-
proving symptoms. Our case report also
suggests another important issue for PEH
and treatment with BV.
A 59-year-old woman was referred
to our hospital in January 2010 with a
pulmonary tumor. She had been followed
up during the previous 10 years for mul-
tiple brain tumors, which had been slowly
glowing. A computed tomography (CT)
scan revealed a 25  35-mm pulmonary
tumor in the right upper lobe with small
ground glass opacities surrounding it (Fig-
ure 1A). An abdominal CT scan showed
multiple low-density areas that were con-
sidered to be hemangiomas on her initial
diagnosis.
A right upper lobectomy was
performed. A histopathological speci-
men showed clusters of CD31-positive
epithelioid cells that had diffusely prolif-
erated into the lung parenchyma with
marked intravascular extensions. Lymph
node metastases and satellite lesions
were also noted around the primary
tumor. These results were compatible with
PEH.
Three months later, she was read-
mitted with a dry cough and respiratory
distress. Her oxygen saturation (SpO2)
was 90% with 5 liter O2 by facemask. A
CT scan revealed diffuse ground glass
opacities in both lung fields (Figure 1B)
and slightly enlarged multiple liver tu-
mors. Because PEH recurrence was highly
suspected because of its clinical course,
combination chemotherapy with carbopla-
tin, paclitaxel, and BV (15 mg/kg) was
initiated. After two cycles of chemother-
apy, the patient showed improvements in
dyspnea and oxygen saturation (SpO2 
95% with 2 liter O2 by nasal cannula). A
CT scan also revealed apparent reduc-
tions of the diffuse ground glass opaci-
ties (Figure 1C) and the liver metastases.
However, this patient unfortunately ex-
perienced the complications of multiple
cerebral infarctions and pneumonia dur-
ing a third cycle of chemotherapy. Her
general status rapidly deteriorated, and
she died 3 months after chemotherapy
was initiated.
Our case showed a relatively ag-
gressive progression considering the
generally dormant nature of PEH. Her
brain tumors had been slowly growing,
although the exact relationship of this
brain tumor and PEH was not clear.
Increased production of vascular endo-
thelial growth factors after pulmonary
surgery might have especially contrib-
uted to the rapid progression of pulmo-
nary infiltrates, as suggested by some
reports.3,4 Because PEH is a rare tumor
of vascular origin, antiangiogenesis
therapy using BV might be a promis-
ing treatment strategy, as suggested by
our case. Our case also illustrates one
of the most serious, albeit uncommon,
adverse effects of BV: cerebral infarc-
tions. Because safety cannot be con-
firmed for these rare vascular tumors,
which commonly metastasize to the
brain, an abundance of caution should
be taken in light of this possibility.
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FIGURE 1. A, Thoracic computed tomography (CT) scan before surgery showed a pulmonary tumor in the right upper lobe.
B, CT scan before chemotherapy revealed diffuse ground glass opacities in both lung fields with pleural effusions. C, CT scan
after two cycles of chemotherapy showed improvements of the diffuse ground glass opacities and bilateral pleural effusions.
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Excision Repair
Cross-Complementing-1
for Small Cell Lung
Cancer
To the Editor:
We read the article by Rossi et
al.1 in the November issue of the Jour-
nal of Thoracic Oncology with great
interest. In the article, the authors
summarized six studies, including our
previous study,2 regarding the expres-
sion of excision repair cross-comple-
menting-1 (ERCC1) in small cell lung
cancer. Overall, the expression of
ERCC1 was not correlated with the
response to platinum-based chemo-
therapy; however, low expression of
ERCC1 was significantly associated
with good prognosis in patients with
limited disease (LD) in three studies.
Based on these data, they speculated
that ERCC1 expression is a prognostic
rather than a predictive marker of re-
sponse to platinum-based chemother-
apy only in patients with LD; how-
ever, they did not take account of the
influence of radiotherapy.
The proportion of patients who
received thoracic radiotherapy was re-
ported in two of the three studies, ex-
cluding the study by Rossi et al.,1 with
35 of 40 (87%) and 38 of 45 (84%)
patients with LD receiving thoracic ra-
diotherapy in the study by Lee et al.3 and
Ceppi et al.,4 respectively. Although the
precise mechanism remains to be eluci-
dated, previous in vitro studies have
shown that low ERCC1 expression is
associated with a high sensitivity to ra-
diation5; therefore, patients who re-
ceived thoracic radiotherapy were ex-
cluded from analysis in our study.2
To date, many studies have been
reported concerning the expression of
ERCC1 also in non-small cell lung can-
cer; however, the results are diverse,
there is no consensus, and it has not
been accepted for clinical use. The role
of ERCC1 is complex, and further stud-
ies are necessary for better understand-
ing of the function of ERCC1 in both
chemoresistance and radioresistance.
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In Response:
The point raised by Kim et al. on
the poorly known role of excision repair
cross-complementing-1 (ERCC1) ex-
pression as predictive marker of radio-
therapy effectiveness in small cell lung
cancer is quite appropriate.
We would like to point out that
48 patients in our series underwent
radiotherapy plus chemotherapy. How-
ever, ERCC1 expression in this sub-
group of patients did not significantly
correlate with clinical objective re-
sponse, even considering the different
disease stage (33 with limited disease
and 14 with extensive disease).
As in the overall population,
ERCC1 was significantly associated
with overall and disease-free survival
but not with response to therapy. Al-
though of limited value, these latter
observations do not seem to confirm a
role of ERCC1 expression with sensi-
tivity to radiation in small cell lung
cancer.
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